PATH vs TELO
Uipath Inc (PATH) versus Telomir Pharmaceuticals, Inc. Common Stock (TELO) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
TELO does not have a complete income-statement cache yet.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. TELO currently screens at market cap $86.0M.
Not investment advice. Open the PATH and TELO stock pages for the full models.
Not investment advice.